M
Maura N. Dickler
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 33
Citations - 9786
Maura N. Dickler is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 27, co-authored 32 publications receiving 8523 citations. Previous affiliations of Maura N. Dickler include Duke University & Cornell University.
Papers
More filters
Journal ArticleDOI
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller,Molin Wang,Julie Gralow,Maura N. Dickler,Melody A. Cobleigh,Edith A. Perez,Tamara Shenkier,David Cella,David Cella,Nancy E. Davidson +9 more
TL;DR: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with pac litaxel alone.
Journal ArticleDOI
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller,Linnea I. Chap,Frankie A. Holmes,Melody A. Cobleigh,P. Kelly Marcom,Louis Fehrenbacher,Maura N. Dickler,Beth Overmoyer,James D. Reimann,Amy P. Sing,Virginia K. Langmuir,Hope S. Rugo +11 more
TL;DR: Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.
Journal ArticleDOI
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Pedram Razavi,Matthew T. Chang,Guotai Xu,Chaitanya Bandlamudi,Dara S. Ross,Neil Vasan,Yanyan Cai,Craig M. Bielski,Mark T.A. Donoghue,Philip Jonsson,Alexander V Penson,Ronglai Shen,Fresia Pareja,Ritika Kundra,Sumit Middha,Michael L. Cheng,Ahmet Zehir,Cyriac Kandoth,Ruchi Patel,Kety Huberman,Lillian M. Smyth,Komal Jhaveri,Shanu Modi,Tiffany A. Traina,Chau T. Dang,Wen Zhang,Britta Weigelt,Bob T. Li,Marc Ladanyi,David M. Hyman,Nikolaus Schultz,Mark E. Robson,Clifford A. Hudis,Edi Brogi,Agnes Viale,Larry Norton,Maura N. Dickler,Michael F. Berger,Christine A. Iacobuzio-Donahue,Sarat Chandarlapaty,Maurizio Scaltriti,Jorge S. Reis-Filho,David B. Solit,Barry S. Taylor,José Baselga +44 more
TL;DR: An increased number of alterations in genes involved in the mitogen-activated protein kinase (MAPK) pathway and in the estrogen receptor transcriptional machinery were identified in breast cancers exposed to hormonal therapy and associated with a shorter duration of response to subsequent hormonal therapies.
Journal ArticleDOI
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
Andrew D. Seidman,Monica Fornier,Francisco J. Esteva,Lee Tan,Stamatina Kaptain,Ariadne M. Bach,Katherine S. Panageas,Crispinita D. Arroyo,Vicente Valero,Violante Currie,Teresa Gilewski,Maria Theodoulou,Mary Ellen Moynahan,Mark M. Moasser,Nancy Sklarin,Maura N. Dickler,Gabriella D'Andrea,Massimo Cristofanilli,Edgardo Rivera,Gabriel N. Hortobagyi,Larry Norton,Clifford A. Hudis +21 more
TL;DR: In this paper, the authors evaluated weekly trastuzumab and paclitaxel therapy in women with HER2 normal and HER2-overexpressing metastatic breast cancer.
Journal ArticleDOI
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler,Sara M. Tolaney,Hope S. Rugo,Javier Cortes,Véronique Diéras,Debra A. Patt,Debra A. Patt,Hans Wildiers,Clifford A. Hudis,Joyce O'Shaughnessy,Esther Zamora,Denise A. Yardley,Martin Frenzel,Andrew Koustenis,José Baselga +14 more
TL;DR: In this poor-prognosis, heavily pretreated population with refractory HR+/HER2− metastatic breast cancer, continuous dosing of single-agent abemaciciclib was well tolerated and exhibited promising clinical activity.